REMEDIUM CAPITAL PARTNERS LLC
Q4 2025 Form 13-F
FORT LAUDERDALE, DELAWARE
CIK 0002104501
· CRD 340302
· SEC-registered investment adviser
$170.2M Reported Value Total
REMEDIUM CAPITAL PARTNERS reports 1 total accounts under management (AUM). There are 1 discretionary accounts valued at $155,000,000, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Source: Form ADV filed 2026-08-20
Reported value
$170.2M
Quarter over quarter
0.0%
Holdings
6
Top-10 concentration
100.0%
Key People
Form ADV owners & control persons
Chad Christopher Hellmann
CHIEF COMPLIANCE OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q4 2025 13F record
Q4 2025 13F filing summary
| Period of report | December 31, 2025 |
|---|---|
| Filed | February 12, 2026 |
| Form | 13F-HR |
| Reported value | $170.2M |
| Positions | 6 |
| Change in reported value | First reported quarter |
| Top-10 concentration | 100.0% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 13, 2026
|
6 | $273.6M |
|
Q2 2026 13F
Filed Aug 7, 2026
|
6 | $451.6M |
|
Q1 2026 13F
Filed May 13, 2026
|
6 | $281.2M |
|
Q4 2025 13F
Filed Feb 12, 2026
|
6 | $170.2M |
Top 6 holdings · Q4 2025
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | SYRE Spyre Therapeutics Inc | $47.7M | 28.03% |
| 2 | ORKA Oruka Therapeutics Inc | $47.1M | 27.64% |
| 3 | APGE Apogee Therapeutics Inc | $44.1M | 25.88% |
| 4 | JBIO Jade Biosciences Inc | $24.3M | 14.3% |
| 5 | CBIO Crescent Biopharma Inc | $4.3M | 2.52% |
| 6 | GLTO Galecto Inc | $2.8M | 1.63% |
Values as reported on the Q4 2025 Form 13F. Every position is in the holdings table below.